Who are Levocabastine HCL's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Benadryl demand, Antihistamine Cetirizine Hydrochloride, Ciclesonide & Levocetirizine, montelukast and cetirizine, fexofenadine HCl, Hydroxyzine HCL.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/levocabastine-hcl.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Levocabastine HCL — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Levocabastine HCL (Levocabastine HCL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: H1-receptor antagonist (selective, non-sedating antihistamine). Area: Immunology / Allergy.

phase 3 H1-receptor antagonist (selective, non-sedating antihistamine) H1 histamine receptor Immunology / Allergy Small molecule Live · refreshed every 30 min

Target snapshot

Levocabastine HCL (Levocabastine HCL) — Chong Kun Dang Pharmaceutical. Levocabastine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Levocabastine HCL TARGET	Levocabastine HCL	Chong Kun Dang Pharmaceutical	phase 3	H1-receptor antagonist (selective, non-sedating antihistamine)	H1 histamine receptor
Benadryl demand	Benadryl demand	University of Pennsylvania	marketed	First-generation H1 antihistamine	H1 histamine receptor
Antihistamine Cetirizine Hydrochloride	Antihistamine Cetirizine Hydrochloride	Goldman, Butterwick, Fitzpatrick and Groff	marketed	H1-receptor antagonist (second-generation antihistamine)	H1 histamine receptor
Ciclesonide & Levocetirizine	Ciclesonide & Levocetirizine	Handok Inc.	marketed	Inhaled corticosteroid + selective H1-receptor antagonist combination	Glucocorticoid receptor (ciclesonide); H1 histamine receptor (levocetirizine)
montelukast and cetirizine	montelukast and cetirizine	Medical University of Lodz	marketed	Leukotriene receptor antagonist and H1-receptor antagonist combination	CysLT1 receptor (montelukast); H1 histamine receptor (cetirizine)
fexofenadine HCl	fexofenadine HCl	Sanofi	marketed	Second-generation H1-receptor antagonist (non-sedating antihistamine)	H1 histamine receptor
Hydroxyzine HCL	Hydroxyzine HCL	National Cancer Institute (NCI)	marketed	First-generation H1 antihistamine	H1 histamine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (H1-receptor antagonist (selective, non-sedating antihistamine) class)

Chong Kun Dang Pharmaceutical · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Levocabastine HCL — Competitive Intelligence Brief. https://druglandscape.com/ci/levocabastine-hcl. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing